Download Full Text (176 KB)
Resident PGY 1
Henry Ford Hospital
Objective: Clinicians have access to a variety of formulations of methylphenidate and amphetamine to treat attention-deficit hyperactivity disorder (ADHD). However, due to new emerging formulations clinicians may lack up-to-date knowledge about all available stimulant formulations. We present a comprehensive guide of 13 formulations of methylphenidate and 10 formulations of amphetamine that have U.S. Food and Drug Administration (FDA) approval to treat ADHD. Methods: A systematic review was completed through PUBMED using the following MeSH terms: “attention-deficit hyperactivity disorder”, “ADHD”, “stimulant”, “amphetamine”, and “methylphenidate”. Conclusions: Each formulation has a unique pharmacokinetic profile. Clinically, one formulation may not be suitable for all patients. This review should provide clinical guidance to help clinicians prescribe the most suitable treatment for an individual.
Gautam, Mohan and Prabhakar, Deepak, "Stimulant formulations for the treatment of ADHD" (2019). Clinical Research. 23.